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Brief summary: A serial cross-sectional serosurvey among primary and secondary care 
patients in Glasgow, Scotland, shows low seroprevalence during the first wave of the 
COVID-19 pandemic and identifies age, sex and caretype as factors associated with 
increased probability of infection. 
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Abstract  
Identifying drivers of SARS-CoV-2 exposure and quantifying population immunity is crucial to 
prepare for future epidemics. We performed a serial cross-sectional serosurvey throughout 
the first pandemic wave among patients from the largest health board in Scotland. Screening 
of 7480 patient sera showed a weekly seroprevalence ranging from 0.10% to 8.23% in 
primary and 0.21% to 17.44% in secondary care, respectively. Neutralisation assays showed 
that around half of individuals who tested positive by ELISA assay, developed highly 
neutralising antibodies, mainly among secondary care patients. We estimated the individual 
probability of SARS-CoV-2 exposure and quantified associated risk factors. We show that 
secondary care patients, males and 45-64-year-olds exhibit a higher probability of being 
seropositive. The identification of risk factors and the differences in virus neutralisation 
activity between patient populations provided insights into the patterns of virus exposure 
during the first pandemic wave and shed light on what to expect in future waves. 
 
Keywords: SARS-CoV-2; COVID-19; Virus exposure, Serology; Virus Neutralisation; 
Modelling; Risk factors; Seroprevalence.     
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Background 
SARS-CoV-2 was first reported in China in December 2019 and spread rapidly across 
multiple countries. The first COVID-19 case in Scotland was confirmed on February 28th, 
2020, the country entered lockdown on March 23rd and restrictions were eased on May 28th 
[1]. Serological surveys are instrumental in determining infection rates at the population 
scale [2]. Assays based on the detection of anti-SARS-CoV-2 IgG antibodies, which are 
typically detectable 7 to 21 days post-infection [3], can identify past viral exposure even in 
asymptomatic individuals. In-house assays commonly utilise an indirect-ELISA format, with 
recombinant S protein, S1 subunit of the S protein or the receptor binding domain (RBD) 
used as antigens. Virus neutralisation assays (VNAs) provide insights into the effectiveness 
of the humoral immune response. Neutralisation titers obtained with pseudotype-based tests 
are similar to those obtained with live virus [4], and two pse dotype-based methodologies 
are commonly used: HIV-based pseudotypes and VSV-based pseudotypes. Both 
methodologies produce similar results [5]. 
Models that link patient information (e.g. age, sex, and time of sampling) with exposure and 
immunity enable the identification of factors associated with SARS-CoV-2 infection [6]. NHS 
Greater Glasgow and Clyde (NHSGGC) is the largest health board in Scotland and reported 
the highest number of COVID-19 cases (n=3876) and deaths (n=1280) in the country 
between March 1st and May 24th, [7]. We performed a serial cross-sectional study amongst 
primary and secondary care patients in NHSGGC to estimate levels of exposure to SARS-
CoV-2 since the introduction of the virus in Scotland and up to calendar week 21 (starting on 
May 18th, 2020). Using a Bayesian framework, we combined serological and patient 
information to estimate an individual’s probability of testing positive for SARS-CoV-2 across 
various age groups, time and healthcare settings. We also performed neutralisation assays 
to estimate the fraction of exposed individuals who developed an effective antibody 
response. Finally, we combined serological data with publicly available information on 
deaths to estimate the case fatality ratio. 
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Methods 
Serum samples  
Ethical approval was provided by NHSGGC Biorepository (application 550). Random 
residual biochemistry serum samples (n= 7480) from primary (general practices) and 
secondary (hospitals) healthcare settings were collected by the NHSGGC Biorepository 
between 16th of March and 24th of May 2020. Associated metadata included date of 
collection, patient sex and age, partial post code of the patient and sample origin (primary or 
secondary care). All serum samples were inactivated at 56oC for 30’ before being tested. 
ELISA testing  
S1 and RBD antigens were prepared as described previously [8]. The SARS-CoV-2 RBD 
and S1 constructs, spanning SARS-CoV-2 S (UniProt ID P0DTC2) residues 319-541 
(RVQPT…KCVNF) and 1-530 (MFVFL…GPKKS), respectively, were produced with C-
terminal twin Strep tags. Proteins were produced by transient expression in Expi293F cells 
grown in FreeStyle-293 medium (Thermo Fisher Scientific). Proteins were harvested at two 
timepoints, 3-4 and 6-8 days post-transfection. Twin Strep-tagged proteins were captured on 
Streptactin XT (IBA LifeSciences) and purified by size exclusion chromatography through 
Superdex 200 (GE Healthcare). Purified SARS-CoV-2 antigens, concentrated to 1-5 mg/ml 
by ultrafiltration were aliquoted and snap-frozen in liquid nitrogen prior to storage at -80oC. 
Assays to detect IgG antibodies against recombinant S1 and RBD antigens of SARS-CoV-2 
were performed as described [9]. 96-well plates (Immulon 2HB, Fisher Scientific) were 
coated overnight with S1 or RBD antigen (50ng/well). After washing three times with 
PBS/0.05%Tween-20 (all subsequent wash steps followed the same protocol), sera were 
diluted 1:100 in PBS/0.05%Tween20 (v/v) supplemented with 10% (v/v) casein (Vector 
laboratories, c/o 2BScientific) and incubated for one hour at room temperature before a 
second wash. Anti-human IgG horseradish peroxidase-conjugated secondary antibody 
(Bethyl laboratories) diluted 1:3000 in PBS/0.05%Tween-20/casein was then added and 
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incubated for one hour before a third wash. 3,3′,5,5′-tetramethylbenzidine (TMB) (Sigma-
Aldrich/Merck) was added and incubated for 10’ in the dark. The reaction was stopped by 
adding an equal volume of 1M H2SO4. Absorbance was read immediately at 450 nm on a 
Labsystems Multiskan Ascent plate reader. Duplicates of pooled known-positive and known-
negative controls were included on each plate. Raw absorbance values were corrected 
using the equation, “(sample absorbance-negative control mean)/negative control mean”. 
This value was used for downstream analysis. The cut-off between positive and negative 
values was selected using receiver operating characteristic (ROC) analysis undertaken 
using the corrected absorbance values of positive and negative control samples tested on 
the assay. 320 serum samples collected before December 2019 obtained from the National 
Institute for Biological Standards and Control (NIBSC) and the Scottish National Blood 
Transfusion Service (SNBTS) were used as negative controls. Positive controls were defined 
as samples from patients with a positive RT-PCR result, or those who had recent clinical 
symptoms consistent with COVID-19 and whose serum sample tested positive on all other 
serological platforms (EUROIMMUN-Anti-SARS-CoV-2 ELISA [IgG], Abbott Architect SARS-
CoV-2 IgG or DiaSorin LIAISON® SARS-CoV-2 S1/S2 IgG). 128 samples were used as 
positive controls. Cut-off values for individual antigens were chosen to optimise for the 
specificity of each individual test, while maintaining a sensitivity above 90%. All samples 
were tested against both S1 and RBD antigens and separate ROC analyses were 
undertaken for each antigen. ROC analyses were performed in GraphPad Prism (GraphPad 
Software) (Supplementary Figure 1). Final sensitivity (Se) and specificity (Sp) values, and 
95% confidence intervals, were calculated by applying the individual cut-off values for S1 
and RBD, derived from the ROC analysis, to the control samples in parallel (i.e. if a sample 
tested positive for either one or both antigens it was considered positive). The resulting 
numbers of true positives and true negatives, and false positives and false negatives, were 
then used to calculate the final sensitivity and specificity of the combined assays. 
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Neutralisation assays 
HEK293, HEK293T, and 293-ACE2 cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% foetal bovine serum, 2mM L-glutamine, 100µg/ml 
streptomycin and 100 IU/ml penicillin. HEK293T cells were transfected with the SARS-CoV-2 
S (corresponding to Wuhan-Hu-1 strain, GenBank MN908947) gene expression vector 
pCDNA6-S (N. Temperton, University of Kent) together with pNL4-3-Luc-E−R−luc [10] using 
polyethylenimine (PEI, Polysciences). HIV (SARS-CoV-2) containing supernatants were 
harvested 48 hours post-transfection, aliquoted and frozen at -80oC before use. 293-ACE2 
target cells were generated by stable transduction of HEK293 cells with pSCRPSY-hACE2. 
Selected 293-ACE2 cells were maintained in complete DMEM supplemented with 2µg/ml 
puromycin. Neutralising antibodies were measured using a fixed dilution screening. 
Duplicate serum samples were diluted 1:50 in complete DMEM and incubated for 1 hour with 
an equal volume of HIV(SARS-CoV-2) pseudotypes. The serum/virus mix was plated onto 
293-ACE2 cells in 96-well white cell culture plates. After 48-72 hours, luciferase activity was 
quantified by adding Steadylite Plus chemiluminescence substrate (Perkin Elmer) and 
analyzed on a Perkin Elmer EnSight multimode plate reader (Perkin Elmer). Sera were 
considered to have high neutralising activity if at a 1:50 dilution they reduced infection by 
HIV(SARS-CoV-2) pseudotypes by ≥90% [11].  
COVID-19 data 
The number of laboratory-confirmed cases was obtained from the Scottish Government 
Website (https://www.gov.scot/coronavirus-covid-19/) and the West of Scotland Specialist 
Virology Centre. The number COVID-19 associated deaths was obtained from the National 
Records of Scotland website (https://www.nrscotland.gov.uk/covid19stats). 
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Statistical analysis 
Multivariable logistic regression models were used to investigate associations between 
neutralisation at a 1:50 dilution and corrected OD values, care-type, age group and sex in 
ELISA positive samples (n=216). Separate models were run for samples positive to S1 and 
RBD (Supplementary Tables 2 and 3). Univariate analyses comparing the mean corrected 
OD, or percent neutralisation, between ELISA positive samples from primary and secondary 
care types were undertaken using Mann-Whitney U tests. To determine a sample size for 
estimating the prevalence of partial postcode districts a simple calculation, assuming a 
random sample from a large population, was used. An assumed prevalence (p) of 10%, and 
a confidence of 95%, substituted into the equation n=1.962p(1-p)/d2 (where 
d=precision=0.05), resulted in a sample size of 138. Statistical analyses and data 
visualisation were undertaken in R [12], version 3.6.1. Models were run using lme4 [13].  
Bayesian state-space model (SSM) 
An SSM was developed to estimate the weekly probability of infection of the patient 
population and to evaluate the impact of the different demographic factors affecting the 
probability of an individual being seropositive for SARS-CoV-2. The model followed methods 
previously published [14] and comprised two coupled parts; a population-level process, and 
an observation or individual-level process. The population process captured the weekly 
exposure dynamics through a linear predictor comprising a temporal trend and 
autocovariates (i.e. first- and second-order AR components capable of reconstructing 
potential exposure cycles). This results in a weekly probability of infection that reflects the 
average chance of being infected in a given week after adjusting for individual covariates in 
the observation process. The observation process confronted the population probabilities by 
using individual-level data (i.e. binary observed serology data from each patient) in a 
Bernoulli trial that adjusted seropositivity according to the sensitivity and specificity of the 
test and estimated an individual’s probability of infection based on the population-level 
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dynamics but also through a series of individual covariates such as sex, age, care type and 
week of sample collection. We noted that since further adjusting for population size resulted 
in differences of ~0.1% in group-based seroprevalence estimates, for simplicity this was 
omitted from the final SSM. We ran the model in JAGS for 100K iterations and 50K burn-in 
to achieve full convergence. Priors and the model code are provided with supplementary 
material. 
Infection fatality ratio (IFR) 
An IFR was calculated for each age group by estimating the fraction of SARS-CoV-2 
confirmed deaths relative to the number of people exposed. The latter variable was 
approximated using the adjusted seroprevalence, multiplied by the corresponding group 
population size (455,739, 310,813, 106,435, and 80,745 for the 18-44, 45-64, 65-74, 75+ 
age groups respectively). Mid-2019 population estimates were obtained from the National 
Records of Scotland (https://www.nrscotland.gov.uk). 
Results 
A total of 7480 residual biochemistry serum samples from patients living in NHSGGC were 
tested for the presence of IgG antibodies against the S1 subunit of the SARS-CoV-2 spike 
protein and its receptor binding domain (RBD) using two ELISA assays [9]. Of these, 6635 
met the inclusion criteria and were used for further analysis. Samples spanned a 10-week 
period, starting on March 16th, 2020 and covered all NHSGGC districts and all age groups, 
except for children and young adults under 18 years of age for whom insufficient samples 
were available (Figure 1 describes the sample inclusion criteria and sample sizes). The 
underrepresentation of samples from paediatric patients reflected the reduction in general 
practitioner appointments, the prioritisation of COVID-19 suspected cases during this period, 
avoidance of attending medical facilities of parents to protect children from the virus, and 
likely reduced risk of non-COVID-19 infections and injuries (the most common reason for 
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emergency attendances in children) due to physical distancing as well as the lower 
incidence of clinical signs in children [15, 16]. 
The overall unadjusted seroprevalence in our patient population was 7.81% (95% CI 7.17-
8.48, Figure 2A). Seroprevalence was higher in the 45-64 year olds, in males, and in 
patients attending secondary care services (Figure 2A). A steady increase in seroprevalence 
from week commencing (w/c) March 16th up to w/c April 13th in both primary and secondary 
care settings was observed. However, while seroprevalence in the secondary care sub-
population was higher, and started to decrease from w/c April 13th, seroprevalence in 
primary care remained at a similar level after w/c 13th April to the end of our study period 
(Figure 2B). For some age groups (45-64y and 64-74y) seroprevalence was higher in men 
(Figure 2C), perhaps driven by a sex bias in SARS-CoV-2-associated hospitalisation [17] 
since men admitted to secondary care services had a higher seroprevalence (10.73%, 95% 
CI 9.40-12.17) than women (7.60%, 95% CI 6.51-8.81; Figure 2C). This difference between 
sexes was not observed among primary care patients (6.06%, 95% CI 4.73-7.63 for men 
and 5.40%, 95% CI 4.29-6.71 for women, Figure 2C). Patient seroprevalence was also 
calculated in a subset (20/61) of districts in which sample numbers provided sufficient power 
to estimate prevalence. Estimated seroprevalence ranged from 3.83% (95% CI 1.67-7.40) to 
12.94% (95% CI 8.29-18.94) (Supplementary Table 1) suggesting that there may be 
geographically-driven differences in infection risk. However, sample size limitations 
prevented more detailed analysis. Our Bayesian state-space model [14] was used to adjust 
the crude patient seroprevalence rates for the sensitivity and specificity of the assays and to 
determine the factors associated with seropositivity in the study population. The model 
converged well and provided a good fit to the data (Figure 3A and Supplementary Figure 2). 
Although the test had high sensitivity (95.31%, 95% CI 90.08-98.26%) and specificity 
(97.20%, 95% CI 94.76-98.71%), the adjusted overall seroprevalence (5.29%, 95% CI 0.13-
15.10) was approximately half the crude estimates (Figure 3A and Table 1). The analysis 
indicated that patients receiving secondary care were twice as likely (odds ratio 2.2, 95% CI: 
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1.6-3.1) to be seropositive compared to those in primary care (Figure 3B). Male patients 
were 1.39 times (95% CI 1.1-1.8) more likely to be seropositive, and individuals belonging to 
the 45-64y age group were 2.2 times (95% CI 1.5-3.3) more likely to be seropositive than 
those in the 18-44y age group. However, belonging to the older age groups (65y+) did not 
significantly increase the probability of being seropositive (Figure 3B). Nonetheless, 
considering the adjusted seroprevalences per age group, and their associated population 
size and SARS-CoV-2 related deaths, we estimated a higher infection fatality ratio (IFR) in 
older age groups (Table 1), which is consistent with a previous UK-based study [18]. The 
probability of infection at the population level (Figure 3C) peaked once during w/c March 
30th, 2 weeks prior to the week with highest seroprevalence and coincided with the peak of 
PCR confirmed cases (Figure 3D). After this peak, there was a low and constant weekly 
probability of infection (median 10.2% [95% CI: 3.1-20.6%]; Figure 3C) likely reflecting the 
strict lockdown conditions of the study period. At the end of study period, before lockdown 
was eased, we observed a slight increase in the probability of infection (Figure 3C), but 
further data would be required for confirmation. Together, these results suggest that while 
levels of infection by SARS-CoV-2 remained broadly constant from the introduction of the 
virus, they were higher among men, 45 to 64-year-old patients, and those who attended 
secondary care.  
To determine if exposure might elicit a protective immune response, HIV(SARS-CoV-2) 
pseudotypes were used to measure levels of neutralising anti-SARS-CoV-2 antibodies in 
samples collected between 24th March and 24th April (n=1974, 10.94% positive by ELISA). 
One hundred and seventeen (54.17%) ELISA positive and 17 (0.97%) ELISA negative 
samples exhibited high neutralising activity (Figure 4A). Sera were considered to have high 
neutralising activity if they reduced infection by >90% at a 1:50 dilution. Overall, our results 
suggest that approximately half of those individuals who seroconverted elicited a highly 
neutralising response. Sera with higher absorbance levels in ELISA assays exhibited higher 
levels of virus neutralisation (Figure 4A; Supplementary Tables 2 and 3). In addition, sera 
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derived from ELISA-positive patients in secondary care displayed significantly higher mean 
absorbance values (p=0.004) (Figure 4B) and mean percent neutralisation when compared 
with sera from antibody-positive patients in primary care (Figure 4C), implying that disease 
severity is associated with a stronger and more effective antibody-mediated response. 
Multivariable logistic regression models confirmed that increasing absorbance values on 
ELISA were significantly associated with neutralisation (OR=1.15, 95% CI 1.10-1.21, 
p=<0.001), and that samples derived from secondary care had significantly higher odds of 
having neutralising ability compared to primary care (OR=6.77, 95% CI 2.68-18.75, 
p=<0.001) (Supplementary Tables 2 and 3).  
 
 
 
 
Discussion 
Serological surveys are key to informing strategies aimed at controlling the spread of 
disease. Our study showed that SARS-CoV-2 exposure during the first wave of the 
pandemic remained broadly consistent over time (likely due to lockdown conditions), but 
heterogeneous among different groups of the Glasgow patient population. After adjustment 
for test sensitivity and specificity, the overall seroprevalence in the patient population of 
NHSGGC (5.29%) was similar to reports from community-based cross-sectional studies 
carried out during an equivalent period in other European cities such as Geneva [19] and 
Madrid [20]. However, as our study relied on analyses of residual biochemistry samples from 
a population of individuals seeking healthcare including -but not exclusively- people who are 
more likely to be symptomatic with SARS-CoV-2 infection than the general population, 
generalisation beyond the study population requires caution. For example, male patients had 
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a significantly higher risk of being seropositive in our study, although this was not a feature 
of the previous community-based studies, likely reflecting a sex bias in COVID-19 
presentation [21] or differences in social behaviour that led to increased exposure [22]. It is 
important to note that 38% of samples were derived from patients attending primary care, 
and this proportion remained stable during the studied period. Under normal circumstances, 
such samples would provide a cost-effective method of obtaining samples for 
serosurveillance that are broadly representative of the wider community [23]. However, the 
unprecedented changes to routine healthcare guidelines and health-seeking behaviour [16] 
during the first wave of the pandemic are likely to have altered the structure of this 
population considerably. Patients in primary care were well enough to be managed in the 
community and so might be subject to similar exposure conditions as the general population. 
At the same time, groups who continued to be seen in primary care for blood sampling, 
including pregnant women and those with chronic conditions, may have shielded during this 
period and thus have had lower exposure than the general population. The prevalence in 
this group may therefore be lower than the expected community prevalence. Conversely, the 
probability of exposure for individuals from secondary care might be higher than expected in 
the general population due to the prioritization of severe COVID-19 cases in hospital settings 
during this period. In addition, some patients may have been in the early stages of infection 
and may not have seroconverted at the time of sampling, resulting in an underestimation of 
seroprevalence in both health care settings. Overall, and with the aforementioned caveats, 
the seroprevalence observed in the primary care subpopulation may be a better 
representation of the general population than that observed in secondary care.  
Neutralisation assays provided insight into post-exposure antibody-mediated immunity. 
HIV(SARS-CoV-2) pseudotype-based neutralisation assays display a high correlation with 
live virus-based assays [4]. Although we found a significant correlation between antibody 
levels and neutralising activity, we also found, in agreement with other studies [24], that 
exposure to SARS-CoV-2 resulted in heterogenous responses. As samples from secondary 
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care patients showed both significantly higher antibody levels and odds of neutralisation 
capacity, our results suggest that disease severity may be associated with more effective 
immune responses. However, antibody levels change over time and our results should be 
considered within this context.  Given the timeframe of our study, our results are likely to 
represent the serological profiles of recent infections. Although our dataset did not include 
clinical information on individual patients, the emphasis on reduction of routine procedures 
and prioritisation of COVID-19 patients during lockdown makes the secondary care 
population a suitable proxy for severe SARS-CoV-2 infections. Lower IgG and neutralising 
responses in primary care patients could also reflect sampling at earlier points post-infection. 
However, similar results linking disease severity and immune response were reported [25-
27]. Neutralising ability observed in a small number of ELISA-negative sera suggests that 
the presence of epitopes outside the SARS-CoV-2 S1 or receptor binding domains may 
contribute to the neutralising response. We note that while there is evidence linking the 
presence of neutralising antibodies with protection [28], any inferences between antibody 
levels and protective immunity should be interpreted with caution. The determinants of a 
protective immune response to SARS-CoV-2 are unknown and recent studies have 
suggested that T cell responses play an important role in SARS-CoV-2 immunity [29]. It has 
been postulated that between 43 and 70% of the population needs to be immune to SARS-
CoV-2 to reach herd immunity [30, 31]. Achieving such levels without vaccination is unlikely 
in the short term given that seroprevalence, even amongst secondary care patients who 
showed the highest seroprevalence, only reached 6.73% (95% CI 0.21-17.44). The absence 
of a strong neutralising response in a large proportion of seropositive patients raises 
questions regarding the protective nature of the humoral immune response, highlighting the 
urgent need for further studies into the duration of neutralising responses and the 
relationship between IgG response, neutralising antibody levels and protection from 
reinfection.  
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Our study provides an insight into the demographic factors that influence SARS-CoV-2 
exposure and immunity. The low prevalence observed, combined with the heterogeneity of 
antibody-mediated neutralising responses suggests that in the absence of measures such as 
vaccination or non-pharmaceutical interventions, future waves of SARS-CoV-2 infection are 
likely to cause significant burden. Future developments in real-time community serological 
surveillance systems linked with robust correlations of virus immunity are necessary to 
design interventions and to prioritize those measures that safeguard public health at a 
minimal societal and economic cost. 
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Figures and captions 
 
Figure 1. Diagram summarizing the flow of samples used in this study. S1: spike 
glycoprotein; RBD: receptor binding domain. 
Figure 2. Unadjusted SARS-CoV-2 seroprevalence in NHS Greater Glasgow and Clyde, 
Scotland, UK, patient population. Seroprevalence estimates and 95% confidence intervals 
are shown across age groups, sex and health care setting (A), or date of sampling (B). Panel 
C shows seroprevalence estimates and 95% confidence intervals investigated in sequential 
combinations of age group, sex, and healthcare setting. 
Figure 3. Posterior estimates obtained from the Bayesian state-space model. (A) Model fit 
(observed data in red vs estimated unadjusted seroprevalence in black) and estimated 
adjusted seroprevalence (grey); (B) Odds ratio of the effect sizes of age, sex and health care 
setting on the probability of a patient being seropositive for SARS-CoV-2 antibodies (95% CI 
lines within violin); and (C) Estimated mean weekly probability of infection of the studied 
population, and associated 75% and 95% CIs. (D) Unadjusted SARS-CoV-2 seroprevalence, 
RT-PCR confirmed COVID-19 cases, and COVID-19 related deaths are shown in red, blue 
and black, respectively. 
 
Figure 4. Antibody levels and subsequent virus neutralisation activity suggest an association 
with disease severity. Correlation between virus neutralisation and antibody production is 
shown as a scatter plot (A), where every sample is represented by a black dot. Percentages 
reflect the sample distribution among seropositive (green), seronegative (red) patients, and 
low (right), or high (left) virus neutralisation. ELISA corrected-absorbance values are shown 
in SARS-CoV-2 seropositive and seronegative patients (B). Virus neutralisation is displayed 
in seropositive and seronegative patients (C). 
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Demographic group 
Population 
size 
Number of 
samples 
Unadjusted 
mean 
seroprevalence 
(95% CI) 
Adjusted mean 
seroprevalence 
(95% CI) 
Covid-19 
related 
Deaths 
IFR 
(%) 
Gender Male 459,189 3,092 9.06 (8.07-
10.12) 
6.49 (0.16-
17.67) 
606 NA 
 Female 494,556 3,543 6.72 (5.92-7.59) 4.23 (0.13-
13.14) 
627 NA 
Care 
type 
Primary NA 2,531 5.69 (4.82-6.66) 2.95 (0.10-
8.23) 
NA NA 
 Secondary NA 4,104 9.11 (8.25-
10.04) 
6.73 (0.21-
17.44) 
NA NA 
Age 
group 
18-44 455,739 1,662 5.05 (4.05-6.22) 3.10 (0.10-
9.05) 
8 0.06 
 45-64 310,813 2,202 9.36 (8.17-
10.65) 
6.67 (0.16-
17.84) 
103 0.50 
 65-74 106,435 1,244 7.48 (6.08-9.08) 5.18 (0.15-
13.98) 
164 2.97 
 >75 80,758 1,527 8.84 (7.46-
10.38) 
5.78 (0.17-
14.96) 
958 20.52 
Overall  953,745 6,635 7.81 (7.17-8.48) 5.29 (0.13-
15.10) 
1233 NA 
 
Table 1. Observed and adjusted seroprevalences (%) in the different demographic groups of 
the GGCHB study population. 
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Figure1 
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Figure 2 
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Figure 3 
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Figure4 
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